| 1. |
- Althin, Rikard, et al.
(författare)
-
Swedish employment offices: A new model for evaluating effectiveness
- 2010
-
Ingår i: European Journal of Operational Research. - : Elsevier. - 0377-2217 .- 1872-6860. ; 207:3, s. 1535-1544
-
Tidskriftsartikel (refereegranskat)abstract
- We measure how well Swedish employment offices perform in delivering the services required of them by the Swedish government. In contrast to earlier studies we use a dynamic efficiency framework, which allows us to better model the intertemporal nature of these services, explicitly allowing for placements of intermediate nature across periods. Rather than using second stage analysis to assess the effects of varying local labor market conditions and differences in client characteristics on performance, we include a measure of the office’s expected work load directly in the model. This measure, derived from duration analysis, is designed to capture the variation across offices in resources needed before an average individual can obtain employment. It is estimated from the characteristics of all unemployed individual and local labor market conditions.The empirical results demonstrate an increase in the office’s expected work loads over time and point to substantial differences in performance across offices. The results also point toward more than optimal placements in intermediate outputs such as non-matching jobs, training, and continued unemployment.
|
|
| 2. |
|
|
| 3. |
- Behrenz, Lars, 1964-, et al.
(författare)
-
An Efficiency Analysis of Swedish Employment Offices
- 2004
-
Ingår i: International review of applied economics. - Abingdon UK : Routledge. - 0269-2171 .- 1465-3486. ; 18:4, s. 471-482
-
Tidskriftsartikel (refereegranskat)abstract
- In this paper the method–production frontier analysis is used to analyse differences in efficiency between different Swedish Employment Offices. Earlier empirical labour market policy evaluation studies have utilised various measures that, however, do not take into consideration differences between organisation units. The main result of this investigation is that employment offices show major differences in the efficiency with which they carry out their job matching services.
|
|
| 4. |
- Behrenz, Lars, 1964-, et al.
(författare)
-
Efficiency and productivity of employment offices: : evidence from Sweden
- 2005
-
Ingår i: International journal of manpower. - Bradford UK : Emerald. - 0143-7720 .- 1758-6577. ; 26:2, s. 196-206
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose – This paper aims to measure the efficiency and productivity of Swedish employment offices. Design/methodology/approach – Using four inputs, five outputs, and two quality attributes the efficiency and productivity of 253 Swedish employment offices are evaluated using models of relative technical efficiency and Malmquist productivity indices. The results are computed as solutions to linear programming problems for the 1992-1995 periods. Findings – Results of the study find that the mean efficiency across offices varies between 74 and 78 percent. The mean productivity change demonstrates a decrease of 11 percent during the 1992-1993 period, and an increase of 7 and 13 percents during 1993-1994 and 1994-1995 respectively. Research limitations/implications – Different background characteristics of job seekers could possibly bias the result for some of the offices. Further research could use a dynamic model where different job seeker characteristics are taken into consideration. Practical implications – The paper provides an opportunity for inefficient/low productivity offices to study how offices identified as more efficient are producing their services. Originality/value – This paper demonstrates how efficiency and productivity could be measured in a multi-input, multi-output employment office service sector setting where quality aspects are allowed to play a part.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Calara, Paul S., et al.
(författare)
-
Healthcare Provider Type and Switch to Biologics in Psoriasis : Evidence from Real-World Practice
- 2016
-
Ingår i: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. - : Springer Science and Business Media LLC. - 1173-8804 .- 1179-190X. ; 30:2, s. 145-151
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Previous research indicates an uneven uptake of biologics in patients with moderate-to-severe psoriasis in Sweden. Therefore, it is essential to scrutinise variations in treatment patterns.OBJECTIVE: The aim of this study was to evaluate the extent to which the uptake of biologics for psoriasis differs between types of healthcare provider.METHODS: Three types of provider were identified within 52 units participating in the Swedish National Registry for Systemic Psoriasis Treatment (PsoReg): university hospitals, non-university hospitals and individual practices. Biologics-naïve patients (n = 3165) were included in analyses to investigate the probability of switch to biologics. The numbers of patients fulfilling the criteria for moderate-to-severe psoriasis [Psoriasis Area and Severity Index (PASI) ≥10 and Dermatology Life Quality Index (DLQI) ≥10] among patients who switched to biologics and patients who did not switch were reported. A logistic regression model was used to calculate how healthcare provider type influenced the probability of switch to biologics whilst adjusting for patient characteristics and disease severity.RESULTS: During registration, 16 % of patients switched to biologics while 84 % remained on conventional systemic treatment. In 7 % of patients, the criteria PASI ≥10 and DLQI ≥10 was fulfilled at their last visit without switching to biologics, whereas in 10 % of patients the criteria was not fulfilled prior to switch. After controlling for patient characteristics and disease severity, small or no difference in the probability of switch was observed between provider types.CONCLUSIONS: Disease severity does not explain the decision to switch or not to switch to biologics for a disproportionate number of patients. There seems to be an uneven uptake of biologics in Swedish clinical practice, but the type of healthcare provider cannot explain this variation. More research is needed on what factors influence the prescription of biologics.
|
|
| 8. |
- Calara, Paul S, et al.
(författare)
-
Regional Differences in the Prescription of Biologics for Psoriasis in Sweden : a Register-Based Study of 4168 Patients
- 2017
-
Ingår i: BioDrugs. - : Springer Science and Business Media LLC. - 1173-8804 .- 1179-190X. ; 31:1, s. 75-82
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Observational studies suggest an inequitable prescription of biologics in psoriasis care, which may be attributed to geographical differences in treatment access. Sweden regularly ranks high in international comparisons of equitable healthcare, and is, in connection with established national registries, an ideal country to investigate potential inequitable access.OBJECTIVE: The aim was to determine whether the opportunity for patients to receive biologics depends on where they receive care.METHODS: Biologic-naïve patients enrolled in the Swedish National Register for Systemic Treatment of Psoriasis (PsoReg) from 2008 to 2015 (n = 4168) were included. The association between the likelihood of initiating a biologic and the region where patients received care was analyzed. The strength of the association was adjusted for patient and clinical characteristics, as well as disease severity using logistic regression analysis. The proportion of patients that switched to a biologic (switch rate) and the probability of switch to a biologic was calculated in 2-year periods.RESULTS: The national switch rate increased marginally over time from 9.7 to 11.0%, though the uptake varied across regions. Adjusted odds ratios for at least one region were significantly different from the reference region in every 2-year period. During the latest period (2014-2015), the average patient in the lowest prescribing region was nearly 2.5 times less likely to switch as a similar patient in the highest prescribing region.CONCLUSIONS: Geographical differences in biologics prescription persist after adjusting for patient characteristics and disease severity. The Swedish example calls for further improvements in delivering equitable psoriasis care.
|
|
| 9. |
- Gralén, Katarina, et al.
(författare)
-
Clinical practice of BOTOX® treatment for overactive bladder syndrome in Sweden : an assessment of resource use and external validity
- 2017
-
Ingår i: Scandinavian Journal of Urology. - : Medical Journals Sweden AB. - 2168-1805 .- 2168-1813.
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: The objective of this study was to assess the resource use of treating overactive bladder (OAB) patients in real-world clinical practice and to evaluate whether there is external validity in the treatment of OAB in clinical practice. Materials and methods: The study included 55 patients suffering from OAB and treated with BOTOX® at two Swedish clinics. The study was conducted as an anonymized retrospective chart review study. Results: The estimated yearly direct cost of BOTOX treatment was €902. The mean age of patients in the study was 60 years, and 85% were women. The severity of OAB before BOTOX treatment, given by the mean number of daily leakages, equalled 4.8. The median interval between treatments was 210 days. Conclusions: Patient characteristics in the real world were similar to those in the clinical trials, showing a high degree of external validity. Treatment intervals were longer in the real world than in clinical trials, indicating that treatment cost could be lower when patients are treated as observed in real-world clinical practice.
|
|
| 10. |
- Welin, Karl-Olof, et al.
(författare)
-
Epilepsy in tuberous sclerosis patients in Sweden – Healthcare utilization, treatment, morbidity, and mortality using national register data
- 2017
-
Ingår i: Seizure. - : Elsevier BV. - 1059-1311. ; 53, s. 4-9
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose This study is designed to estimate the prevalence of epilepsy associated with TSC in Sweden and to describe treatment, morbidity, and mortality of TSC patients with epilepsy. Methods Register data for 2004–2014 was obtained from the National Board of Health and Welfare in Sweden. Patients with TSC were identified using ICD-10 codes. Epilepsy was identified using ICD-10 codes, interventions aimed to treat epilepsy, or prescriptions for antiepileptic drugs. Results The prevalence of TSC was 5.38 per 100 000 individuals. We identified 551 unique patients with TSC, of which 386 (70.1%) had epilepsy. The mean study period was 8.82 years. Antiepileptic drugs were dispensed to 97.9% of patients with epilepsy. The most prescribed antiepileptic drug was sodium valproate. Ketogenic diet was used in 6 (1.6%) patients, vagus nerve stimulation in 23 (6.0%) patients, and epilepsy surgery was performed in 25 (6.5%) patients. The mean number of outpatient visits per year was 4.70 (SD 4.17) and the mean number of inpatient days per year was 3.25 (SD 5.61). The mean number of outpatient visits per year with an ICD-10 code for epilepsy was 1.65 (SD 1.95) and the corresponding number of inpatient days was 2.06 (SD 4.50). A total of 30 patients with TSC and epilepsy died during the study period. Conclusions The prevalence of epilepsy in this study was in the lower range of previously reported numbers, suggesting that epilepsy may be overestimated in non-population based studies. A substantial part of the healthcare utilization was directly related to epilepsy.
|
|
